Application of thiazole substituted derivative in inflammatory lung injury
The substitution of thiazole of the derivative PY-60 promotes the expression of the Hippo pathway and related factors, solves the problem of decreasing regeneration ability of alveolar type II epithelial cells, realizes effective treatment of inflammatory lung injury, and provides new drug applications for ARDS.
Patent Information
- Application Number
- CN202411180720.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-27
- Publication Date
- 2024-11-29
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The prior art cannot effectively promote the regeneration of alveolar type II epithelial cells, resulting in the inability to repair the damage to alveolar epithelial cells in patients with ARDS, and lack of effective treatment methods.
The regeneration and repair of alveolar type II epithelial cells was promoted by promoting protein phosphorylation of Hippo pathway-related factors YAP and TAZ, as well as the expression of HGF, EGF and TGF-α.
It significantly improves the regeneration ability of alveolar type II epithelial cells, reduces inflammatory lung damage, improves the repair ability of lung tissue, and provides an effective treatment method for ARDS.
Smart Images

Figure CN119033778A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of drugs for treating inflammatory lung injury, and in particular to application of a thiazole substituted derivative in treating inflammatory lung injury. Background Art
[0002] Acute respiratory distress syndrome (ARDS) is a clinical syndrome of refractory hypoxemia, respiratory insufficiency and even respiratory failure caused by infection, shock, burns and trauma. Its pathological characteristics are diffuse alveolar damage caused by inflammatory damage to pulmonary capillary endothelial cells and alveolar epithelial cells. In the pathological process of ARDS, the repair and protection functions of alveolar epithelial cells are significantly impaired. The alveolar epithelium is composed of two types of cells, flat alveolar type I epithelial cells (AECI) that cover 95%–98% of the alveolar surface and allow gas exchange, and cuboidal alveolar type II epithelial cells (AECII) with differentiated stem cell functions. In the lung organ, the biological process of maintaining renewal and regeneration and repair of alveolar epithelium after injury is mainly driven by the differentiation of alveolar type II epithelial cells into alveolar type I epithelial cells. After the lung tissue is damaged by diseases such as inflammation, alveolar type II epithelial cells can self-renew and differentiate into alveolar type I epithelial cells to maintain the integrity of the alveolar structure and normal gas exchange function. In the pathological process of ARDS, the regeneration and repair ability of alveolar type II epithelial cells is impaired, resulting in the inability to self-repair after inflammation, which aggravates the damage of the disease. So far, the treatment of ARDS worldwide is mainly symptomatic support. There is no effective drug that can promote the regeneration of alveolar type II epithelial cells with stem cell function to achieve the repair of damaged alveolar epithelial cells and thus treat ARDS. Summary of the invention
[0003] The purpose of the present invention is to provide an application of a thiazole substituted derivative in inflammatory lung injury. The present invention uses the thiazole substituted derivative to prepare a drug for treating inflammatory lung injury, thereby achieving the purpose of treating inflammatory lung injury.
[0004] The technical solution provided by the present invention is as follows: application of thiazole substituted derivatives in inflammatory lung injury, wherein the thiazole substituted derivatives are used to prepare a drug for treating inflammatory lung injury.
[0005] In the above application, the administration of the drug includes inhalation, oral administration, intravenous injection, intramuscular injection or airway instillation,
[0006] The medicine can be an inhalation preparation, an oral preparation, an intravenous injection preparation, an intramuscular injection preparation or an airway instillation preparation; the oral preparation includes capsules, granules, and tablets; the inhalation preparation includes sprays, aerosols, dry powder inhalers or a combination thereof.
[0007] In the above application, the thiazole substituted derivative is PY-60, and the structural formula is as follows:
[0008]
[0009] The aforementioned application, wherein the drug comprises PY-60 as an active ingredient, and a pharmaceutically acceptable carrier;
[0010] The active ingredient is in the form of liquid and / or solid inhalable particles;
[0011] The pharmaceutically acceptable carrier includes a propellant, a dispersant, a surfactant, a liquid carrier and / or a solid carrier.
[0012] In the aforementioned application, the subject to which the drug is applied includes humans or non-human mammals, preferably humans, mice or rats.
[0013] In the aforementioned application, the drug achieves the purpose of treating inflammatory lung injury by promoting the regeneration of alveolar type II epithelial cells.
[0014] In the aforementioned application, the drug achieves the purpose of treating inflammatory lung injury by promoting the expression of Hippo pathway related to regeneration and repair.
[0015] In the aforementioned application, the drug achieves the purpose of treating inflammatory lung injury by promoting the expression of YAP and its protein phosphorylation level and / or TAZ and its protein phosphorylation level, which are key factors of the Hippo pathway related to regeneration and repair in lung tissue.
[0016] In the aforementioned application, the drug achieves the purpose of treating inflammatory lung injury by promoting the expression of regeneration and repair related factors HGF, EGF and TGF-α.
[0017] In the aforementioned application, the drug is composed of PY-60 and a cosolvent, wherein the concentration of PY-60 is 1 mg / kg.
[0018] In the aforementioned application, the cosolvent comprises 10% DMSO, 40% PEG300, 5% Tween-80 and 45% physiological saline by volume.
[0019] Compared with the prior art, the present invention confirms that alveolar type I and type II epithelial cells are damaged after inflammatory lung injury, and the regeneration ability of alveolar type II epithelial cells with "stem cell" function decreases; therefore, the present invention uses thiazole substituted derivatives to prepare drugs for treating inflammatory lung injury, which can promote the expression of Hippo pathway key factor YAP and its protein phosphorylation level and / or TAZ and its protein phosphorylation level, thereby promoting the regeneration of alveolar type II epithelial cells, achieving the purpose of treating inflammatory lung injury. The present invention provides a new application of thiazole substituted derivatives, which is convenient for the treatment of inflammatory lung injury. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 This is a schematic diagram of drug administration for constructing an airway inflammation and injury disease model by airway instillation of LPS;
[0021] Figure 2 Schematic diagram of the damage of alveolar epithelial cells in the acute inflammatory lung injury model;
[0022] Figure 3 This is the result of immunofluorescence staining of lung tissue to mark cell nuclei and alveolar type II epithelial cell markers;
[0023] Figure 4 yes Figure 3 Statistical graphs of labeled cell nuclei and alveolar type II epithelial cell markers;
[0024] Figure 5 The lung tissue western-blot was used to detect the expression of YAP and p-YAP, a key factor in the Hippo pathway related to regeneration and repair;
[0025] Figure 6 The western-blot of lung tissue was used to detect the expression of TAZ and p-TAZ, key factors in the Hippo pathway related to regeneration and repair;
[0026] Figure 7 This is the HE pathological staining of lung tissue and the lung injury degree score diagram;
[0027] Figure 8 is a graph of inflammatory cell counts in bronchoalveolar lavage fluid;
[0028] Fig. 9 It is a graph of immunofluorescence staining of lung tissue to mark cell nuclei, alveolar type II epithelial cell markers and cell proliferation markers and statistical results;
[0029] Fig.10 This is the result of ELISA detection of HGF, EGF and TGF-ɑ, factors related to epithelial cell regeneration and proliferation in bronchoalveolar lavage fluid;
[0030] Fig.11This is the result of Western-blot detection of YAP and its protein phosphorylation level in lung tissue;
[0031] Fig.12 This is the result of Western-blot detection of TAZ and its protein phosphorylation levels in lung tissue. DETAILED DESCRIPTION
[0032] The present invention is further described in detail below in conjunction with specific embodiments, and the examples given are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way. The experimental methods in the following examples, unless otherwise specified, are conventional methods, and are carried out according to the techniques or conditions described in the literature in this area or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial sources.
[0033] Example: Application of thiazole substituted derivatives in inflammatory lung injury.
[0034] 1. Construction of mouse model of acute lung injury:
[0035] Dissolve 100 mg of lipopolysaccharide (LPS) powder in 10 ml of sterile phosphate buffered saline (PBS) to prepare a 10 mg / ml stock solution and store at -20 °C. Dilute to 5 mg / ml solution with PBS when used. Weigh the body weight of 6-8 week old healthy C57BL / 6 male mice, inject 1% pentobarbital (0.2 mL / mouse) intraperitoneally, and after the mice are anesthetized, instill LPS into the airways of the mice (dosage 10 mg / kg, dosing volume 50 μL), and stand the mice upright for 2 minutes to allow the drug to diffuse evenly in the lungs of the mice. Observe the respiratory rate of the mice, ensure that the respiratory rate of the mice is stable, place them on a warming blanket, and put them back in the cage after they wake up. The same volume of PBS was instilled into the trachea of the control mice in the same way. Monitor the condition of the mice regularly, and observe the mental state, hair condition, and eating conditions of the mice. Collect model mouse samples at the time points required by the experiment.
[0036] 2. Preparation of thiazole substituted derivative drugs;
[0037] In this embodiment, the thiazole substituted derivative is PY-60, which is a specific activator (Kd=1.4 μM) of YAP transcriptional activity targeting annexin A2 (ANXA2). The structural formula is as follows:
[0038]
[0039] The present invention uses the PY-60 to prepare a drug for treating inflammatory lung injury. The drug in the present invention may contain a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" refers to a carrier used for administering a therapeutic agent. The term refers to such pharmaceutical carriers: they themselves do not induce the production of antibodies that are harmful to the individual receiving the composition, and there is no excessive toxicity after administration. These carriers are well known to those of ordinary skill in the art. A full discussion of pharmaceutically acceptable excipients can be found in Remington's Pharmaceutical Sciences (Mack Pub. Co., NJ 1991). Such carriers include (but are not limited to): saline, buffer, glucose, water, glycerol, ethanol, adjuvants and combinations thereof.
[0040] Pharmaceutically acceptable carriers in therapeutic drugs may contain liquids, such as water, saline, glycerol and ethanol. In addition, auxiliary substances, such as wetting agents or emulsifiers, pH buffer substances, etc., may also be present in these carriers.
[0041] Typically, drugs are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution or suspension in liquid vehicles prior to injection can also be prepared.
[0042] These drugs can be formulated by mixing, diluting or dissolving according to a conventional method, and appropriate pharmaceutical additives such as excipients, disintegrants, binders, lubricants, diluents, buffers, isotonicities, preservatives, wetting agents, emulsifiers, dispersants, stabilizers and solubilizers are occasionally added, and the formulation process can be carried out in a conventional manner according to the dosage form.
[0043] Once formulated, the drug of the present invention can be administered by conventional routes, including (but not limited to): oral, intramuscular, intravenous, subcutaneous, intradermal, intratracheal, mucosal, or topical administration. The subject to be prevented or treated can be an animal; especially a human.
[0044] The pharmaceutical composition of the present invention can also be administered in the form of a sustained-release agent. For example, the active ingredient of the present invention can be incorporated into a pill or microcapsule with a sustained-release polymer as a carrier, and then the pill or microcapsule is surgically implanted into the tissue to be treated.
[0045] When the drug of the present invention is used for actual treatment, the dosage of the active ingredient of the present invention or its pharmaceutically acceptable salt as the active ingredient can be reasonably determined according to the body weight, age, sex, and symptom severity of each patient to be treated.
[0046] The PY-60 of the present invention and a pharmaceutically acceptable carrier form an inhalation preparation. Generally, the inhalation preparation may include an aerosol, a spray, a dry powder inhaler or a combination thereof. Preferably, the inhalation preparation of the present invention may be an aerosol.
[0047] When the inhalation preparation of the present invention usually requires dispersing the active ingredient in a pharmaceutical carrier to obtain an inhalation preparation in the form of inhalable microparticles, the dispersion system includes a solvent, a suspension or an emulsion.
[0048] When the active ingredient of the present invention is a dry powder inhaler, the active ingredient of the present invention can be made into dry particles using conventional techniques, such as preparing dry particles by drying, grinding, sieving, etc. The active ingredient of the present invention can be appropriately mixed with a suitable dispersant (e.g., lactose). Of course, other dispersants can also be used for preparation.
[0049] In addition, the inhalation preparation of the present invention may also include a propellant, such as a hydrocarbon or a compressed gas, such as air, nitrogen, carbon dioxide, dichlorodifluoromethane, trichlorofluoromethane or nitrous oxide, so that the inhalation preparation of the present invention can pass through the narrow nozzle of the nebulizer and pass through the human nasal cavity or oral cavity in an accelerated manner.
[0050] In this example, 25 mg of PY-60 drug was dissolved in 7.98 ml of DMSO to prepare a storage solution with a final concentration of 10 mM. On the day of the experiment, the storage solution was added with a medical cosolvent. The cosolvent formulation is shown in Table 1 below:
[0051] concentration 10mM stock solution 10% DMSO 40% PEG300 5% Tween-80 45% saline Total volume 0 0 280μL 1120μL 140μL 1260μL 2800μL 0.1mg / kg 11.169μL 278.8831μL 1115.5324μL 139.44155μL 1254.97395μL 2800μL 1mg / kg 111.689μL 268.8311μL 1075.5324μL 134.44155μL 1209.97395μL 2800μL 10mg / kg 1.116891mL 168.3109μL 673.2436μL 84.1555μL 757.3995μL 2800μL
[0052] Table 1
[0053] 3. PY-60 drug treatment of acute lung injury: LPS airway instillation to establish an acute lung injury model (day 0, day 0), the methodology is the same as above. Figure 1 As shown, on day 1, day 3, and day 5, the prepared PY-60 drug was intraperitoneally injected at 0.1 mg / kg, 1 mg / kg, and 10 mg / kg, respectively. 24 hours after the last administration, that is, on day 6, the model was treated and samples were collected for testing.
[0054] 4. Sample collection: Collect alveolar lavage fluid, serum, lung tissue, etc. to assess the degree of inflammation.
[0055] (A) Collection of bronchoalveolar lavage fluid (BALF): 24 h after the last administration, mice were anesthetized and killed, and the neck and chest skin of mice were disinfected with alcohol. The skin was cut open, the chest cavity was opened, and the surrounding soft tissues were carefully removed to expose the trachea and lungs. A 1 ml syringe and a 20G needle were used to form a lung lavage device, and 500 μL of pre-cooled PBS buffer was drawn. Carefully puncture and insert the mouse trachea and be careful not to damage the airway with the syringe needle. The PBS solution was quickly pushed into the mouse lungs, causing the mouse lungs to expand rapidly. After 1 min, the alveolar lavage fluid was slowly withdrawn and the collected lavage fluid was transferred to a centrifuge tube. Repeat three times. The centrifuge tube was transferred to ice for temporary storage for subsequent inflammatory cell counting. Total white blood cells were counted, and eosinophils, neutrophils, monocytes, and lymphocytes were counted separately to obtain the percentage of each type of cell and calculate the absolute value of each type of cell.
[0056] (B) Bronchoalveolar lavage fluid (BALF) was collected using the same method as above, and the concentrations of HGF (Hepatocyte growth factor), EGF (Epidermal growth factor), and TGF-α (Transforming growth factor-α) were detected by ELISA, referring to the instructions of the kit.
[0057] (C) Collection of lung tissue: The mice were killed by cervical dislocation and fixed on a dissecting board. The skin of the neck and chest was disinfected with alcohol cotton balls, and the skin, tissue and thorax were cut to expose the trachea and lungs. The heart located between the 3rd and 4th ribs on the left side was clamped with forceps in the left hand, and a 1 ml syringe was held in the right hand to puncture the heart at the position where the heart beats the strongest, and the heart was bled to death. The heart lobe was moved to the right side, and the left lobe was ligated with silk thread. The heart lobe and the right three lobes were freed and temporarily stored in liquid nitrogen / dry ice, and then transferred to a -80℃ ultra-low temperature refrigerator for storage. The trachea was cut open, and a 20G needle was inserted and connected to a 1 ml syringe. 0.2 ml of 4% paraformaldehyde was perfused to expand the left lung (internal fixation), and the tracheal opening was ligated. The lung lobe after internal fixation was freed and placed in 4% paraformaldehyde (external fixation).
[0058] (D) Fixed lung tissue will be used for HE pathological staining, immunofluorescence, and Western-blot experiments, according to conventional experimental methodology.
[0059] (E) RNA-seq transcriptome sequencing analysis of lung tissue, conventional methodology.
[0060] 5. Experimental results:
[0061] Figure 2 Schematic diagram of the damage of alveolar epithelial cells in the acute inflammatory lung injury model. Figure 2As can be seen in the figure, lung tissue transcriptome sequencing (RNA-seq) found that the expression of alveolar type I (A) and type II epithelial cell markers (B) decreased, indicating damage to the alveolar epithelium. Immunofluorescence staining of lung tissue, such as Figure 3 As shown, the cell nucleus (DAPI) and alveolar type II epithelial cell marker (Sftpc) were labeled. Figure 4 Statistical diagram of labeled cell nuclei (DAPI) and alveolar type II epithelial cell marker (Sftpc), ***P<0.001. Figure 3 and Figure 4 It can be found that the proportion of Sftpc-positive cells decreased significantly, confirming that inflammatory lung injury leads to damage of alveolar epithelial cells.
[0062] Figure 5 The lung tissue western-blot was used to detect the expression of YAP and p-YAP, a key factor in the Hippo pathway related to regeneration and repair; Figure 6 The expression of TAZ and p-TAZ was detected by western-blot in lung tissue, *P<0.05, ***P<0.001. Figure 5 and Figure 6 The results suggested that inflammatory lung injury led to decreased expression of YAP and TAZ.
[0063] Figure 7 The following is a graph of lung tissue HE pathological staining and lung injury degree scoring. The results confirmed that PY-60 at a dose of 1 mg / kg could significantly reduce lung injury. Bronchoalveolar lavage fluid was collected and total inflammatory cells, neutrophils, macrophages, and lymphocytes were counted. Figure 8 As shown, *P<0.05, ***P<0.001. The results suggest that PY-60 can significantly reduce the recruitment of the above inflammatory cells at a dose of 1 mg / kg. This confirms that PY-60 can improve alveolar congestion and edema, alleviate alveolar destruction, and achieve the purpose of treating inflammatory lung injury.
[0064] LPS was dripped into the airway to establish an inflammatory lung injury model, and PY-60 was dripped into the airway for local administration. Lung tissue was immunofluorescently stained to mark cell nuclei (DAPI), alveolar type II epithelial cell marker (Sftpc) and cell proliferation marker (ki67). The statistical results showed that Fig. 9 As shown. Fig. 9 It can be seen that the proliferation ability of alveolar type II epithelial cells in diseased mice treated with PY-60 was significantly enhanced (Sftpc+Ki67+ / DAPI+ percentage). ELISA was used to detect HGF, EGF and TGF-ɑ, factors related to epithelial cell regeneration and proliferation in bronchoalveolar lavage fluid. Fig.10As shown in Figure 2, the results suggest that PY-60 treatment significantly promoted the expression of the above factors. Western-blot detection of YAP and its protein phosphorylation levels in lung tissue, as shown in Figure 2 Fig.11 As shown, Western-blot was used to detect the phosphorylation level of TAZ in lung tissue. Fig.12 as shown. Fig.11 and Fig.12 The results showed that PY-60 treatment significantly increased the expression of the above proteins. *P<0.05, ***P<0.001.
[0065] In summary, the present invention confirms that alveolar type I and type II epithelial cells are damaged and their regeneration ability decreases after inflammatory lung injury; therefore, the present invention uses thiazole substituted derivatives to prepare drugs for treating inflammatory lung injury, which can promote the expression of the Hippo pathway and its key factor YAP and protein phosphorylation level and / or TAZ and protein phosphorylation level related to regeneration and repair, promote the expression of regeneration and repair related factors HGF, EGF and TGF-α, and then promote the regeneration of alveolar type II epithelial cells, enhance the repair ability of epithelial cells after damage, and achieve the purpose of treating inflammatory lung injury. The present invention provides a new application of thiazole substituted derivatives, which is convenient for the treatment of inflammatory lung injury.
[0066] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any changes or substitutions that can be easily conceived by any technician familiar with the technical field within the technical scope disclosed by the present invention should be covered within the protection scope of the present invention.
Claims
1. The use of thiazole substituted derivatives in inflammatory lung injury, characterized in that: The thiazole substituted derivative is used for preparing medicine for treating inflammatory lung injury.
2. The use according to claim 1, characterized in that: The administration of the drug includes inhalation, oral administration, intravenous injection or airway instillation.
3. The use according to claim 1, characterized in that: The thiazole substituted derivative is PY-60, and the structural formula is as follows:
4. The use according to claim 1, characterized in that: The drug comprises PY-60 as an active ingredient and a pharmaceutically acceptable carrier.
5. The use according to claim 1, characterized in that: The drug achieves the purpose of treating inflammatory lung injury by promoting the regeneration of alveolar type II epithelial cells.
6. The use according to claim 1, characterized in that: The drug achieves the purpose of treating inflammatory lung injury by promoting the expression of Hippo pathway related to regeneration and repair.
7. The use according to claim 1, characterized in that: The drug achieves the purpose of treating inflammatory lung injury by promoting the expression of YAP and its protein phosphorylation level and / or TAZ and its protein phosphorylation level, which are key factors of the Hippo pathway related to regeneration and repair in lung tissue.
8. The use according to claim 1, characterized in that: The drug achieves the purpose of treating inflammatory lung injury by promoting the expression of regeneration and repair related factors HGF, EGF and TGF-α.
9. The use according to claim 2, characterized in that: The drug consists of PY-60 and a cosolvent, wherein the concentration of PY-60 is 1 mg / kg.
10. The use according to claim 9, characterized in that: The cosolvent includes 10% DMSO, 40% PEG300, 5% Tween-80 and 45% physiological saline by volume.
Citation Information
Patent Citations
Small molecule activators of YAP transcriptional activity for regenerative organ repair
CN117222407A
